key: cord-1002147-8wg3ikh5
authors: Lim, Yong Kwan; Kweon, Oh Joo; Kim, Hye Ryoun; Kim, Tae-Hyoung; Lee, Mi-Kyung
title: Field Evaluation of Seven SARS-COV-2 Antigen Assays
date: 2021-12-23
journal: J Infect Public Health
DOI: 10.1016/j.jiph.2021.12.012
sha: fb29b8aa1d362d4e4100ffc516a0d7ac84ca2a26
doc_id: 1002147
cord_uid: 8wg3ikh5

There is a global demand for rapid diagnostic tests (RDTs) for Coronavirus disease 2019 (COVID-19), and the interest in their clinical compliance is growing. In this study, we evaluated the clinical compliance of seven different severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antigen RDTs. Nasopharyngeal/oropharyngeal swab specimens from COVID-19-confirmed cases and reverse-transcription PCR (RT-PCR) screening were used to evaluate the performance of seven RDTs. Using the RT-PCR and RDT results, we predicted the cycle threshold (Ct) of each target gene (E, RdRP, and N genes) which 50% (Ct(50)) and 95% (Ct(95)) detection rates were achieved in the RDTs. A total of 482 specimens were enrolled in our study: 316 specimens from COVID-19-confirmed cases and 166 RT-PCR-negative specimens. The median values of Ct(50) and Ct(95) for the seven RDTs were in the ranges of ranged 24.3‒30.9 and 19.3‒22.6 for E, 25.5‒31.5 and 20.9‒24.0 for RdRP, and 26.8‒32.3 and 22.7‒25.7 for N, respectively. The RDTs showed acceptable compliance only for specimens with high viral burdens (Ct < 20). However, the false-negative rate increased by more than 50% for most of the RDTs in low-viral burden specimens (Ct > 30). These results suggest that RDTs should not be used without molecular assays for COVID-19 screening for asymptomatic patients because of their high false-negative rates.

Since the rapid, worldwide spread of the novel coronavirus strain, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Coronavirus disease 2019 (COVID-19) has become the leading public health concern [1] . Although molecular assays are considered the gold standard for the diagnosis of SARS-CoV-2 infection, the drawbacks of PCR-based assays, such as long turnaround times and high running cost, pose several problems in a "PCR-only"-based diagnostic testing program [2] . Antigen (Ag) rapid diagnostic tests (RDTs) for the detection of SARS-CoV-2 have become attractive options for several countries lacking resources and skilled laboratory staff to perform complex PCR assays [3] . Although many RDTs have been evaluated for their performance and are actually used in various countries [3] [4] [5] [6] , there is still a growing demand for the evaluation of RDTs in real-world clinical settings. In this study, we evaluated the clinical compliance of seven SARS-CoV-2 antigen RDTs and compared their results with those of a molecular assay using nasopharyngeal swabs. 

Antibody kinetics and serologic profiles of SARS-CoV-2 infection using two serologic assays

Evaluation of two rapid antigen tests to detect SARS-CoV-2 in a hospital setting

Comparison of seven commercial SARS-CoV-2 rapid point-of-care antigen tests: a single-centre laboratory evaluation study

Comparative Clinical Performance of Four SARS-CoV-2 Rapid Antigen Tests and Their Correlation to Infectivity In Vitro

Field evaluation of the performance of a SARS-CoV-2 antigen rapid diagnostic test in Uganda samples

Clinical assessment of the Roche SARS-CoV-2 rapid antigen test. Diagnosis (Berl)

Protocol for Evaluation of Qualitative Test Performance

PA: Clinical and Laboratory Standards Institute

Evaluation of SARS-CoV-2 antigen-based rapid diagnostic kits in Pakistan: formulation of COVID-19 national testing strategy

Testing for SARS

COVID-19): a systematic review and clinical guide to molecular and serological in-vitro diagnostic assays

Evaluation of rapid antigen test for detection of SARS-CoV-2 virus